Brad Loncar is CEO of Loncar Investments, a firm that specializes in the creation of precision biotechnology investment indexes. Its first two products are The Cancer Immunotherapy Index and The China BioPharma Index. Mr. Loncar has been an independent biotechnology industry investor and has managed a biotech-focused family portfolio from his Lenexa, Kansas office since 2008. He previously worked in the financial services industry at Franklin Templeton Investments where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at www.LoncarBlog.com and has contributed opinion pieces to Endpoints News and Xconomy.com.